Hessekiel Jeffrey

Avg. Two Year Performance

No purchase track record
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return----------
Purchase Success Rate----------
Average Sale Return< 1%3%(5%)(2%)0%
Sale Success Rate2 of 132 of 131 of 130 of 130 of 13

Exelixis, Inc.

Drugs » Biotechnology

EVP & General Counsel:

Holdings: 516.65K shares

Sentiment

Insider Trading Sentiment: Reduce

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--